Jeffrey Epstein, New York Financier and Harvard University Help Combat the Evolution of Cancer
The Jeffrey Epstein VI Foundation Backs Pivotal research on the evolution of cancer cells.
The mathematical model was developed by Martin Nowak, Director of the Program for Evolutionary Dynamics at
By developing a mathematical model of colon cancer cell growth during treatment with an inhibitor drug, (which typically blocks a protein receptor), Nowak and his team, showed how the KRAS gene is not actually activated or ‘switched on’ from inhibitor drugs but rather a small percentage of colon cancer cells with an already activated KRAS gene are immune from the start and evolve to predominance as the other cancer cells are destroyed by the inhibitor drug.
The discovery was critical in changing the approach to inhibitor drug therapy. Instead of applying a single inhibitor drug, which can lead to a resilient minority to dominate, the Pathology and Oncology Department at John Hopkins are now exploring the use of a cocktail of drugs to block all colon cancer cell types: those with the activated KRAS gene and those without. The same approach is underway for other cancer types.
“The use of mathematics in biology is an exciting new field,”
Much research still needs to be done: cocktail tolerance needs to be assessed, and cocktails have to be specific to cancer types and minority cells known to be resistant.
The Jeffrey Epstein VI Foundation established the Program for Evolutionary Dynamics at
SOURCE The Jeffrey Epstein VI Foundation